IgG Next Generation is a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma for the treatment of immunodeficiencies and autoimmune diseases.
IgG Next Generation has been approved in Germany and Austria under the trade name Yimmugo®. Submission in further European countries and USA will follow soon. Clinical development has been successfully completed in two pivotal trials: phase III Study No. 991 for the treatment of patients with primary (congenital) immunodeficiencies (PID) and phase III Study No. 992 for the treatment of patients with immune thrombocytopenia (ITP). Final results of both studies confirm the expectations regarding efficacy and safety of the drug. The development for further indications is planned.